Compounding Pharmacy Issues Recall
US Compounding, Inc. issues voluntary recall of all sterile products.
FDA announced on Sept. 21, 2015 that US Compounding has voluntarily recalled all lots of sterile products compounded and packaged by the company; non-sterile compounded products are not being recalled. The recall is in response to FDA’s concern regarding a lack of sterility assurance. The affected lots were distributed nationwide between March 14, 2015 and Sept. 9, 2015.
US Compounding states, in a press release, that “If the sterility of a compounded preparation intended to be sterile is compromised, patients may be at risk. As USC takes the utmost care to ensure patient safety and out of an abundance of caution, then, USC is asking all patients and providers that received sterile compounded products from USC between March 14, 2015 and September 9, 2015, and that remain within expiry, to take the following actions: discontinue use of the products; quarantine any unused product until further instructions are received on how to return the product; and contact USC at 800.718.3588 x254 or 501.327.1222 x254 from the hours of 8:30AM-5:00PM central time Monday-Friday, or e-mail at questions@uscompounding.com to discuss the return of any unused sterile compounded products.”
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
